Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

remazolam

Phase 1Small molecule

SSichuan Provincial People's Hospital

remazolam is one of 59 small molecule programs targeting Delirium. It is currently in Phase 1.

2

Indications

2

Total Trials

1

Active Trials

58

Competitors

Pipeline

Status by Indication[3][1]

Indication

DeliriumActive, not recruiting

AnesthesiaNot yet recruiting

DeliriumPreclinical

Active, not recruiting

AnesthesiaPhase 1

Not yet recruiting

Competition

Competitive Landscape

77 competitors in Delirium

#DrugCompanyPhaseTrials

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Exelon

Rozerem

Seroquel

EEngelhard Arzneimittel GmbH & Co.KG

Aleve

Jazz Pharmaceuticals

Voltaren

Duragesic

Ketalar

AAultman Health Foundation

Anerem

AAcacia Pharma Ltd

Spravato

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Anesthesia1 trial

Effect of Remazolam on Anesthesia Recovery in Patients Undergoing Fundus Surgery

Not yet recruiting·SSichuan Provincial People's Hospital·Phase 1·NCT06205719·93 enrolled

Delirium1 trial

The Role of Remazolam in Reducing the Incidence of Postoperative Delirium in Elderly Patients

Completed·FFang Jun·N/A·NCT05466279·131 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for remazolam. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — remazolam compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for remazolam. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sichuan Provincial People's Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: SSichuan Provincial People's Hospital

Related News